MAPK pathway mutations, such as BRAF and RAS, increase the likelihood of PTC occurrence, evolution, and prognosis, while the PI3K-AKT pathway leads to FTC through mutations like RAS, PIK3CA, and AKT1. The gene discussed is PIK3CA; the disease is thyroid cancer, nonmedullary, 2.